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Interleukin-33 during Homeostasis and
Inﬂammation: Strong Species Differences
Olav Sundnes1,2, Wojciech Pietka1,2, Tamara Loos2, Jon Sponheim1,2, Andrew L. Rankin3, Stefan Pﬂanz3,
Vibeke Bertelsen2, Jan C. Sitek4, Johanna Hol1,2, Guttorm Haraldsen1,2 and Denis Khnykin1,2
IL-33 is a novel IL-1 family member with a putative role in inﬂammatory skin disorders and a complex biology.
Therefore, recent conﬂicting data regarding its function in experimental models justify a close assessment of its
tissue expression and regulation. Indeed, we report here that there are strong species differences in the
expression and regulation of epidermal IL-33. In murine epidermis, IL-33 behaved similar to an alarmin, being
constitutively expressed in keratinocyte nuclei and rapidly lost during acute inﬂammation. By contrast, human
and porcine IL-33 were weakly expressed or absent in keratinocytes of noninﬂamed skin but induced during
acute inﬂammation. To this end, we observed that expression of IL-33 in human keratinocytes but not murine
keratinocytes was strongly induced by IFN-γ, and this upregulation completely depended on the presence of
EGFR ligands. Accordingly, IFN-γ increased the expression of IL-33 in the basal layers of the epidermis in human
ex vivo skin cultures only, despite good evidence of IFN-γ activity in cultures from both species. Together these
ﬁndings demonstrate that a full understanding of IL-33 function in clinical settings must take species-speciﬁc
differences into account.
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INTRODUCTION
IL-33 is an IL-1 family member that has gained considerable
interest after reports of a role in inﬂammatory skin diseases
such as atopic dermatitis (AD) and psoriasis (Hueber et al.,
2011; Savinko et al., 2012). First described as a nuclear factor
in endothelial cells (Baekkevold et al., 2003), it was later
identiﬁed as the signaling ligand for the orphan IL-1 family
receptor ST2, currently referred to as IL-33R (Schmitz et al.,
2005). Signaling through this receptor has been studied in
great detail in a wide range of inﬂammatory conditions
(Palmer and Gabay, 2011). IL-33R is expressed on various
hematopoietic and stromal cells, including group 2 innate
lymphoid cells, that are highly responsive to IL-33 and appear
to be crucial for immune responses and tissue homeostasis
(Monticelli et al., 2011; Imai et al., 2013; Mchedlidze et al.,
2013; Salimi et al., 2013).
Two important factors currently limit our understanding of
IL-33. One factor is that, unlike most cytokines, IL-33 also
appears to exert receptor-independent, transcriptional effects
in the nucleus of stromal cells such as ﬁbroblasts, endothelial,
and epithelial cells (Carriere et al., 2007), thereby acting as a
dual-function immune mediator in the same manner as high
mobility group box-1 (HMGB1; Haraldsen et al., 2009).
Another factor is that the exact conditions and mechanisms of
extracellular release remain unclear. Although cellular
necrosis appears to be the main mode of release (Palmer
and Gabay 2011), some reports suggest cell type–speciﬁc,
active secretion through mechanical stretch or ATP exposure
(Kouzaki et al., 2011; Kakkar et al., 2012; Byers et al., 2013).
A putative role for IL-33 in inﬂammatory skin diseases is
based on the observation that polymorphisms in the IL-33R
gene correlate with an increased risk of AD (Shimizu et al.,
2005) and that administration of recombinant IL-33 (Rankin
et al., 2010; Hueber et al., 2011), transgenic overexpression
(Imai et al., 2013), neutralizing antibodies (Byrne et al., 2011),
or lack of the IL-33 receptor (Hueber et al., 2011; Salimi et al.,
2013) can affect inﬂammation. However, recently published
data in murine models of AD have been contradictory (Kim
et al., 2013; Salimi et al., 2013) and more data are clearly
needed to fully understand its potential as a therapeutic target.
These considerations and previously reported differences
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between murine and human vascular IL-33 expression
(Pichery et al., 2012) prompted us to carefully compare the
expression of IL-33 in both murine, porcine, and human skin
and allowed us to observe important species differences of
IL-33 expression in vivo and in vitro. This study demonstrates
that comparative data are important to bridge the gap
between murine experimental models and a full under-
standing of IL-33 function in clinical settings.
RESULTS
Marked differences in constitutive IL-33 expression in murine
and human skin
IL-33 expression in normal murine epidermis has been
reported (Pichery et al., 2012; Imai et al., 2013) but not
explored in detail. Immunohistochemical analysis conﬁrmed
that IL-33 was constitutively expressed in the nuclei of
keratinocytes but revealed no signal in their cytoplasm
(Figure 1a). Interestingly, and previously unreported, IL-33
was also expressed in peripheral sebocytes (Figure 1a and e)
of the pilosebaceous unit (Tóth et al., 2011). We conﬁrmed
the speciﬁcity of our staining using normal skin from IL-33− /−
mice (Supplementary Figure S1a online) or a different
antibody to IL-33 in wild-type mice (Supplementary Figure
S1b–d online). IL-33 expression was completely restricted to
keratin 14–positive basal keratinocytes (Figure 1b) and absent
from distal K1– or loricrin–positive layers (Figure 1c–d). IL-33
was generally not expressed in vascular endothelial cells in
mouse skin (data not shown).
In obvious contrast to the prominent constitutive IL-33
expression in murine keratinocytes, human IL-33 signal was
generally low in normal human epidermis (Figure 1f), as also
reported by others (Hueber et al., 2011; Meephansan et al.,
2012), showing only weak signal mainly restricted to nuclei
of K10-positive suprabasal keratinocytes corresponding to
the stratum spinosum (Figure 1g–i). By contrast, vascular
endothelial cells were the dominant constitutive source of
IL-33 in human skin (Figure 1j). Paired immunostaining
combining the monoclonal antibody (Nessy-1) with a poly-
clonal antibody gave almost complete colocalization and
conﬁrmed the nuclear localization of IL-33 (Supplementary
Figure S1e–g online).
IL-33 behaves as an alarmin during early acute skin
inﬂammation in murine epidermis
To map the expression of IL-33 during acute inﬂammatory
events in mouse skin, we ﬁrst examined the spatial and
temporal response to skin wounding. In an ear punch model,
we observed that IL-33 disappeared from keratinocytes at the
wound margin at 6 hours (Figure 2a) and that these became
necrotic at 24 hours (Figure 2b). However, 3 days post
wounding, there was strong IL-33 expression in several layers
of the thickened epidermis (Figure 2c). IL-33 expression was
reduced to normal levels upon wound closure at day 7
(Figure 2d).
To further explore the possible early release of constitu-
tively expressed epidermal IL-33, we injected live Staphylo-
coccus aureus intradermally, observing after 6 hours that the
IL-33 signal disappeared from keratinocytes and sebocytes in
the center of the lesion but remained detectable in the
periphery (Figure 2e and g). There were no signs of overt
epidermal necrosis. Immunostaining for the prototype alarmin
HMGB1 indicated nuclear integrity and the possibility of
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Figure 1. Expression of IL-33 in normal murine and human skin. Formalin-ﬁxed, parafﬁn-embedded specimens of wild-type mouse skin were stained by
immunoenzymatic method (a) or by paired immunoﬂuorescence staining for IL-33 (red) and epidermal differentiation markers (all green) keratin (KRT) 14 (b–e),
KRT 1 (c), or loricrin (d). Panel e shows high-power view of mouse sebaceous gland (SG) and hair follicle (HF). Normal human skin was stained for IL-33 (f, red) or
costained with differentiation markers (all green) KRT 14 (g), KRT 10 (h), and loricrin (i). Panel j shows high-power view of dermal blood vessel with IL-33 (red)
and vascular marker VE-Cadherin (green). Nuclear stain with Topro-3 or Hoechst (blue) as indicated. Dotted lines indicate dermoepidermal junction.
Bar=50 μm.
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prenecrotic secretion of IL-33 (Figure 2f and h). At the edge
of the lesion, we observed strong induction of nuclear IL-33
in dermal, heat-shock protein 47+ ﬁbroblasts (Kuroda and
Tajima, 2004; Figure 2j and k), whereas costaining for CD45
revealed no evidence for IL-33 expression in hematopoietic
cells (Figure 2l).
After 24 hours, nuclear IL-33 and HMGB1 had disappeared
from the lesion and at this time the epidermis was clearly
necrotic (Supplementary Figure S2a–c online). In biopsies
extending beyond the necrotic area, we observed a clear
watershed between IL-33-positive and IL-33-negative epider-
mis (Supplementary Figure S2d online).
Human and porcine IL-33 behaves as an inﬂammation-induced
factor in keratinocytes in the early wound healing response
In human wound healing IL-33 expression remained weak in
suprabasal K10+ cells after 6 hours (Figure 3a–c). After
24 hours, we observed strong induction in nuclei of basal
keratin 14+ cells that express nondetectable levels of IL-33 in
noninﬂamed skin (Figure 3d–f). By contrast, endothelial IL-33
expression was reduced (Supplementary Figure S3a and b
online), consistent with our previously published observation
that IL-33 is downregulated in endothelial cells by
proinﬂammatory cytokines in vitro and in vivo (Küchler
et al., 2008). Four days after wounding, the epidermal IL-33
IL-33 HSP47 IL-33 CD45 Topro-3
IL-33 HMGB1 Topro-3 IL-33 HMGB1 Topro-3
6 h 24 h 3 d 7 d
e and f
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Figure 2. Constitutively expressed IL-33 is rapidly lost from murine keratinocytes during acute skin inﬂammation. Panels a–d show immunoenzymatic staining
for IL-33 (brown) of formalin-ﬁxed, parafﬁn-embedded specimens from murine ear wounds at different time points. Subpanels e–l show immunostaining of
samples injected intradermally with S. aureus 6 hours before tissue harvest. Immunoenzymatic staining for IL-33 (brown) is shown at different locations in the
lesion in panels e, g, i, and j. Panel k shows IL-33 (brown) combined with immunoenzymatic staining for ﬁbroblast marker heat-shock protein 47 (HSP47; red).
Panels f and h shows paired immunoﬂuorescent staining for IL-33 (red) and high mobility group box-1 (HMGB1; green), panel l shows paired staining for IL-33
(red) and CD45 (green), as well as Topro-3 nuclear counterstain (blue). Bar=50 μm.
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expression was markedly reduced but still stronger than in
normal skin (Figure 3g–i). By contrast, the prototype alarmin
HMGB1 was constitutively expressed in most nuclei in the
epidermis and showed no modulation in response to
wounding (Supplementary Figure S3c–e online).
These ﬁndings indicated that keratinocyte-derived IL-33 is
an inﬂammation-induced factor and not a constitutively
expressed alarmin in the human epidermis. To further corro-
borate these species differences, we also examined a skin
wounding model in the pig, a species in which both the
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Figure 3. IL-33 expression is induced in keratinocytes during acute inﬂammation in human and porcine skin. Formalin-ﬁxed, parafﬁn-embedded specimens
from a time series of human wound healing (at 6 hours, 24 hours and 4 days post wounding) and porcine wound healing (normal skin and 24 hours post
wounding) were examined with immunoﬂuorescent staining for IL-33 (red) alone (a, d, g, j, and m) or combined with differentiation markers (all green) keratin
(KRT) 14 (b, e, h, k, and n) or KRT 10 (c, f, i, l, and o). Nuclear staining with Hoechst or topro-3 (blue) as indicated. Dotted lines indicate dermoepidermal
junction. Bar=50 μm.
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immune system and skin architecture more closely resemble
man (Sullivan et al., 2001; Dawson et al., 2013). We found
that noninﬂamed porcine skin had strong endothelial signal
for IL-33, whereas expression of IL-33 in the epidermis was
undetectable (Figure 3j–l and Supplementary Figure S3f
online). Moreover, 24 hours after wounding, there was clear
induction of IL-33 in keratinocytes at the wound edge (Figure
3m–o and Supplementary Figure S3g online), therefore very
closely resembling the regulation pattern of human skin.
Although the induction was not as marked as that seen in the
human model, it indicates that porcine epidermal IL-33 also
acts as an inﬂammation-induced factor.
IL-33 is upregulated in human keratinocytes by interferon
gamma in an EGFR ligand–dependent manner
To better understand what drives IL-33 expression during
inﬂammation in the human epidermis, we looked at regula-
tion in cultured primary keratinocytes. Conﬂuent unstimu-
lated monolayers of normal human keratinocytes contained a
small proportion of IL-33-expressing cells (Figure 4a), much
unlike human endothelial cells in which most cells express
nuclear IL-33 upon conﬂuence (Supplementary Figure S4a–b
online). Both observations were in good agreement with what
is seen in vivo.
Next, we exposed keratinocytes to a wide range of pro-
inﬂammatory cytokines and agonists (data not shown) and
found only IFN-γ to strongly induce IL-33 expression
(Figure 4b). This ﬁnding was conﬁrmed at the transcriptional
level (Figure 4e, upper panel) and is in agreement with other
recent reports (Meephansan et al., 2012; Seltmann et al., 2013).
By contrast, murine keratinocytes (thriving and proliferating
in vitro) failed to express IL-33 and were insensitive to cytokine
activation (data not shown), suggesting that additional factors
are needed to drive IL-33 in murine keratinocytes.
The immunoﬂuorescent signal of IL-33 in human keratino-
cytes was restricted to the nucleus (Figure 4a–c), and
subcellular fractionation of cellular lysates conﬁrmed
that IFN-γ mainly induced nuclear IL-33 accumulation
(Supplementary Figure S4d–f online). Recent reports show
that IL-33 secretion responds to ATP and calcium signaling in
lung epithelial cells (Kouzaki et al., 2011; Byers et al., 2013),
yet we did not observe either modulation of the nuclear
signal, cytoplasmic translocation, or IL-33 in supernatants
after stimulation with thapsigargin, ATP, or a wide range of
other proinﬂammatory stimuli in keratinocytes (data not
shown). On the other hand, IL-33 was readily detectable by
ELISA in cell lysates, responding to IFN-γ stimulation in a
dose-dependent manner (Supplementary Figure S4c online)
and indicating the potential of IL-33 release upon cell
necrosis.
We found that two different EGFR tyrosine kinase inhibitors
(also recently published by Meephansan et al. (2012)) or the
EGFR-neutralizing antibody cetuximab completely abolished
the IFN-γ-induced upregulation and showed a trend to reduce
the basal expression levels in unstimulated keratinocytes
(Figure 4d and Supplementary Figure S4g–I online). On the
other hand, although stimulation of keratinocytes with
recombinant EGF increased the phosphorylation of EGFR
(data not shown), it induced no upregulation of IL-33
(Figure 4d). Analysis with a lactate dehydrogenase release
assay revealed no signs of inhibitor-associated toxicity (data
not shown). Given that the supplements in the commercial
keratinocyte growth medium contain EGFR ligands (personal
communication, CELLnTEC), we removed them, observing
that IFN stimulation failed to increase IL-33 expression
(Figure 4f). Moreover, addition of either recombinant EGF or
other EGFR ligands such as amphiregulin, heparin-binding
EGF-like growth factor, and transforming growth factor-α was
sufﬁcient to restore IL-33 inducibility. Together, these data
show that EGFR signaling alone is insufﬁcient to upregulate
IL-33 expression above basal levels but that EGFR ligands are
necessary to permit the action of IFN-γ.
Next we asked whether the IFN-γ-induced, EGFR-
dependent response was relevant for other cytokine responses
in keratinocytes (Figure 4e). We ﬁrst observed that the IFN-γ
responsiveness of the chemokine CXCL10 was not reduced by
simultaneous EGFR inhibition (Figure 4e, middle panel).
Moreover, thymic stromal lymphopoietin, a Th2-inducing
epithelium-derived cytokine, was strongly upregulated by the
TLR3-agonist poly I:C but unaffected by IFN-γ or EGFR
inhibition (Figure 4e, lower panel). These results indicate that
the keratinocyte response leading to IL-33 induction is not a
general inﬂammatory activation scheme but rather a distinct
pathway.
Ex vivo skin organ cultures support species-speciﬁc regulation
Taken together, our in vivo and in vitro ﬁndings suggest that
IL-33 is an inﬂammation-induced factor in human keratino-
cytes. To further explore this assumption, we used a human
ex vivo skin organ culture model. Normal human skin
cultured ex vivo for 48 hours in growth medium alone
showed no upregulation of IL-33 in the epidermis but reduced
endothelial IL-33 (Figure 5a). However, adding IFN-γ to the
medium induced a strong IL-33 signal in the basal keratino-
cytes after 24 hours (Figure 5b), closely resembling our in vivo
observation after wounding. Induction of a nuclear pSTAT1
signal in all keratinocyte layers revealed a direct response to
IFN-γ (Figure 5 c–f). RT-PCR analysis showed the induction of
IL-33 transcripts (Figure 5g), and western blot of tissue lysates
showed a strong increase in full-length IL-33 (Figure 5h), both
observations supporting our immunohistochemical ﬁndings.
Murine skin cultured ex vivo showed an epidermal
distribution of IL-33 similar to that seen in vivo (Figure 5i
and Figure 1a) and no further increase in response to IFN-γ
(Figure 5j), despite induction of nuclear pSTAT1 (Figure 5 k–
n). RT-PCR analysis showed no signiﬁcant induction of IL-33
transcripts (Figure 5o). Western blotting conﬁrmed the
presence of full-length IL-33 in the tissues and no increase
in response to rmIFN-γ (Figure 5p). Taken together, these data
conﬁrm the differential regulation of IL-33 in human and
murine epidermis.
DISCUSSION
Recent studies that address the function of IL-33 in the skin
have generated partly contradictory data, and it appears that
one important reason may be our insufﬁcient understanding
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Figure 4. IFN-γ induces IL-33 in human keratinocytes in an EGFR-dependent manner. Unstimulated (a) or IFN-γ stimulated (b and c) keratinocytes were
costained for IL-33 (red) and keratin (KRT) 14 (green; a and b) or for IL-33 alone (c). Panel d shows ELISA and western blot of IL-33 in lysates of human
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RT-PCR data for gene transcripts il33, cxcl10, and tslp in normal human keratinocytes (NHKs) stimulated (6 hours) with the same combinations of IFN-γ and EGFR
inhibitors or with TLR3-agonist poly(I:C) alone. ELISA and RT-PCR data are presented as mean± SD of biological triplicates. ***P⩽0.001 (increase vs.
unstimulated), ###P⩽0.001 (reduction vs. IFN-stimulated), §§P⩽0.01 (increase vs. INF-stimulated; calculated using one-way analysis of variance with Tukey’s
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of its cellular expression modes, modalities of action, and
species differences. Here we have carefully mapped the tissue
expression of IL-33 in mouse, pig, and man during the onset
of inﬂammation, and correlated our in vivo observations to
in vitro studies of keratinocytes and ex vivo culture of skin.
We observed several interesting differences, noting that the
mouse has modes of constitutive expression and regulation
quite distinct from those observed in swine and man, and
concluding that such differences need consideration in future
assessment of cytokine function.
The ﬁrst strong difference relates to the assumption that
IL-33 acts as an alarmin stored in cell nuclei and released in
response to cellular stress, either by an unconventional
secretory mechanism or following necrosis. In man, pig, and
several other mammals, IL-33 is constitutively expressed at
high levels in the vascular endothelium, whereas it is
practically absent from murine blood vessels (Carriere et al.,
2007; Küchler et al., 2008; Pichery et al., 2012, this paper,
and our unpublished observations). Instead, it appears that the
dominant source that may provide alarmin function of IL-33
in normal murine skin are epidermal keratinocytes. This was
supported by the observation that the constitutively expressed
murine IL-33 in basal keratinocytes was lost rapidly during
acute inﬂammatory events. Although the loss of IL-33 from
keratinocyte nuclei suggests some form of release, we cannot
exclude the alternative that the protein is quickly down-
regulated and degraded. Unfortunately, cultured primary
mouse keratinocytes did not express IL-33 protein in our
hands and currently prevents us from understanding these
mechanisms. Nevertheless, the epidermal lesion became
overtly necrotic within 24 hours and therefore correlates the
loss of IL-33 to irreversible cell damage.
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Figure 5. Ex vivo organ culture supports species-speciﬁc differences. Normal human (a–h) or murine (i–p) skin was cultured for 48 hours ex vivo in the absence
or presence of IFN-γ (100 ngml−1) for the last 24 hours. Immunostaining (brown) was performed for human (a–b) and mouse IL-33 (i–j). Double
immunoﬂuorescent staining for IL-33 (red) with pSTAT1 (green, c, d, k, and l) or for pSTAT1 alone (green, e, f, m, and n). Nuclear staining with Topro-3 (blue).
Experiments were repeated three or more times. Bar= 50 μm. RT-PCR for il33 (g and o) and western blot for IL-33 and tubulin (h and p) were performed on tissue
lysates from human and murine tissue with or without stimulation with IFN-γ. RT-PCR graphs show mean± SD. Mann–Whitney test was performed using
GraphPad Prism 6. *Po0.001. NS, nonsigniﬁcant (P= 0.342).
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By contrast, although human and porcine keratinocytes
displayed low or absent expression of IL-33 in the steady
state, they showed strong upregulation 24 hours after skin
wounding. Hence, IL-33 cannot be considered a prestored
alarmin in the human and porcine epidermis, but rather an
inﬂammation-induced factor. Furthermore, we could mimic
the strong upregulation of IL-33 in an ex vivo organ culture by
exposing human skin to IFN-γ, whereas the same stimulus had
no effect on IL-33 regulation in murine skin.
The signiﬁcance of these species differences is currently
difﬁcult to explain. The immune system develops in response
to the environment, and it is not surprising that immune
functions at barrier surfaces of humans and rodents may
have evolved differently (Mestas and Hughes, 2004). One
possibility is that the IL-33 expression reﬂects the function of
an endogenous, nuclear factor rather than that of a soluble
cytokine. This could be supported by the fact that although
IL-33 is only found in mammals (Ogryzko et al., 2014) a
search in the NCBI gene database shows that IL1RL1, the gene
coding for the IL-33R, is also described in non-mammals such
as zebraﬁsh (Geer et al., 2010). This is interesting in an
evolutionary perspective and could indicate that IL-33R
gained ligand-binding capacity at a later evolutionary stage,
whereas IL-33 may have had its evolutionary origin as a
nuclear factor before emerging to serve as a ligand. To this
end, there is already convincing evidence in experimental
arthritis that IL-33- and the IL-33R-deﬁcient mice have
different outcomes (Martin et al., 2013). One possibility is
that IL-33R has another, yet unidentiﬁed, ligand or a ligand-
independent function, but the ﬁndings could also be
attributed to nuclear targeting during synthesis of IL-33 and
a distinct intracellular function. Indeed, intracellular IL-33 can
have opposite effects on NF-κB signaling in the producing cell
than that of released IL-33 (Ali et al., 2011), and these ﬁndings
make it even more important to consider the expression
patterns when considering the biology of IL-33. Another
example is the contradiction of results obtained in AD-like
mouse models: Kim et al. (2013) showed that lesion
development is IL-33-independent, whereas Salimi et al.
(2013) showed a clear dependence of IL-33 in the same
model. It is possible that these differences may be caused by
the use of either IL-33-deﬁcient mice (Kim et al., 2013) or
IL-33R-deﬁcient mice (Salimi et al., 2013).
Pathways studied with experimental models should resem-
ble their human counterparts in order to understand the
translational potential. Indeed, the strong differences seen
here are important to consider when extrapolating results
from murine models. Nevertheless, it is important to note that
although we show clear species differences there was
increased IL-33 expression also in the inﬂamed murine
epidermis (Figure 2c), and thus it does not exclude that the
mouse is a sustainable model to understand IL-33 biology in
chronic skin inﬂammation. However, the signals involved in
driving epidermal IL-33 in the mouse are, according to our
data, clearly different from those driving human IL-33 and
crucial to understand when devising strategies to target IL-33
production.
In human keratinocytes, we found that IFN-γ was the most
potent signal driving IL-33 production. IFN-γ is a key cytokine
both in innate and adaptive immune responses. It is over-
expressed in psoriasis and also in the chronic phase of AD
(Bieber, 2008), yet not thought to be a feature in acute AD
lesions. It is therefore currently unclear whether this pathway
is involved in early phases of AD or whether there are other
regulatory mechanisms that induce epidermal IL-33 in this
setting.
We also observed that IFN-γ-induced IL-33 induction was
completely dependent on EGFR signaling and that several
different EGFR ligands could confer the IFN-γ-induced IL-33
response. Although the ligands tested are all relevant to human
epidermis and can be produced by keratinocytes themselves, it
is of particular interest that amphiregulin appears to be linked
to the biological function of IL-33. Amphiregulin is known to
be potently induced in innate lymphoid cells upon IL-33
stimulation in both lung and skin, and this is thought be
important for tissue homeostasis in mouse (Monticelli et al.,
2011) and man (Salimi et al., 2013). One can therefore
envision an amplifying loop in which IL-33 released from
damaged keratinocytes potently drives synthesis of amphir-
egulin in innate lymphoid cells that then feeds back to facilitate
further IL-33 expression in nearby, viable keratinocytes.
In conclusion, we here give a detailed account on the
expression and regulation of IL-33 in the human epidermis
in vitro and in vivo and reveal distinct differences between
human and murine skin. To know whether and how to target
IL-33 in a therapeutic setting, it will be important to
understand the implications of the expression patterns, in
particular the possible intracellular effects and the relative
contribution of different sources of IL-33 in vivo. With the
crucial role of IL-33 in activation of immune cells, strategies
targeting IL-33 production in the epidermis could potentially
be useful in the treatment of AD and other inﬂammatory skin
diseases.
MATERIALS AND METHODS
Reagents
Recombinant human IFN-γ, IL-1β, EGF, amphiregulin, heparin-
binding EGF-like growth factor, transforming growth factor-α,
recombinant mouse IFN-γ, and poly(I:C) were from R&D Systems
(Minneapolis, MN), AG1478 was from Sigma (St Louis, MO),
PD15035 was from Tocris (Bristol, UK), and Cetuximab was from
Merck Serono (Darmstadt, Germany). Primary antibodies are listed in
the Supplementary Information online.
Animal procedures
All animal experiments were performed according to national
legislation and with institutional approval. Murine protocols were
performed in 8- to 16-week-old mice on C57BL/6 background. Ear
wounds were performed with a 2-mm punch biopsy tool (PFM
Medical, Cologne, Germany). Live S. aureus (Strains ATCC27217 or
SH1000) was injected intradermally in back skin as a 25-μl bolus
(2.5× 106 C.F.U.) in sterile saline. At the indicated time points, mice
were euthanized and lesions were collected, immediately ﬁxed in
formalin for 24 hours at 4 °C, and processed further for parafﬁn
embedding.
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Porcine skin wounds were made in 55-kg domestic pigs under light
sedation and in local anesthesia with a 3.5-mm punch biopsy tool at
the upper back. Wounds were not sutured but covered with a
dressing. Lesions were collected with an 8-mm punch biopsy tool
after 24 hours and processed as described above.
Human tissues and human skin wounding model
Human tissue was obtained in accordance with the Declaration of
Helsinki Principles and protocols were approved by the Regional
Committee for Research Ethics. Normal human skin samples
(abdominal and breast skin) were obtained during plastic surgery from
Caucasian women aged 40–55 years after informed written consent.
The human skin wound model was performed on a male Caucasian
volunteer after informed written consent. Punch biopsies (3mm) were
taken from the upper arm and the wound left open but covered with a
dressing until collection of 8-mm punches biopsies that surrounded the
initial wounds. All biopsies were immediately formalin-ﬁxed for
24 hours at 4 °C and processed for parafﬁn embedding.
Cell culture
Primary human neonatal keratinocytes and murine keratinocytes
(CELLnTEC, Bern, Switzerland) were cultured in serum-free prolifera-
tion medium (CnT-57 or CnT-07, respectively) from CELLnTEC. Cells
were split before reaching conﬂuence, and all experiments were
performed at passage 3–6 one day after reaching conﬂuence.
Ex vivo skin organ culture
Eight-milimeter punch biopsies of normal human skin or of shaved
normal murine back skin were cultured on custom-made metal mesh
stands in six-well plates ﬁlled with culture medium (DMEM (Carlsbad,
CA) supplemented with 10% fetal calf serum and 100Uml−1 Penicillin
and 100 μgml−1 Streptomycin) to the level of the epidermis for 48 hours.
IFN-γ was added to the culture medium during the last 24 hours.
Samples were either formalin-ﬁxed or homogenized in TriReagent (Life
Technologies, Grand Island, NY) or SDS lysis buffer (as described in
Grøvdal et al. (2004)) using a FastPrep-24 tissue homogenizer (MPBio,
Santa Ana, CA) with a 1/4” ceramic bead as lysing matrix.
Immunohistochemistry and cytochemistry
Sections (3 μm) of formalin-ﬁxed, parafﬁn-embedded samples were
mounted to Superfrost Plus slides (Menzel-Gläser, Braunschweig,
Germany) and deparafﬁnized before antigen retrieval in either TrisEDTA
buffer (pH9) or Target Retrieval Solution (Dako, Copenhagen, Denmark,
pH6) at 100 °C (20min) in a water bath. Blocking was performed with
5% donkey serum (20minutes) before slides were incubated with
primary antibodies either overnight (4 °C) or 30–60minutes (20 °C),
followed by either ﬂuorescent or immunoenzymatic detection. Cells
were cultured on LabTek eight-well chamber slides (Thermo Fisher
Scientiﬁc, Rochester, NY) and ﬁxed with 4% paraformaldehyde. All
antibodies were incubated with 0.1% saponin for permeabilization.
Primary antibodies were incubated overnight at 4 °C. Detailed staining
protocols are given in the Supplementary Materials and Methods online.
ELISA
Keratinocytes were grown and stimulated in 12-well plates, lysed
in 200 μl of M-PER lysis buffer (Thermo Fischer Scientiﬁc,
Waltham, MA) supplemented with protease inhibitor cocktail (Sigma,
St Louis, MO), and lysates were analyzed with human IL-33 DuoSet
ELISA (R&D Systems) according to the manufacturer’s protocol.
Absorbance was recorded with an Epoch microplate reader (BioTek,
Winooski, VT).
Western blot analyses
Keratinocytes and tissues were lysed in SDS lysis buffer (as described in
Grøvdal et al. (2004)) containing protease inhibitor cocktail (Sigma) and
phosphatase inhibitor cocktail 2 (Sigma). Immunoreactive proteins in
cell lysates or tissue lysates were detected using SuperSignal West Dura
Extended Duration Substrate (Thermo Fischer Scientiﬁc) and visualized
using the ChemiDoc MP System (Bio-Rad Laboratories, Hercules, CA).
RT-PCR
RNA was isolated from normal human keratinocytes using TriReagent
(Life Technologies) according to the manufacturer’s instructions.
Tissue lysates were puriﬁed on RNeasy columns (Qiagen, Hilden,
Germany). Total RNA was reverse-transcribed using Oligo(dT) and
SuperScript III Reverse Transcriptase (Life Technologies). Gene
transcripts were quantiﬁed by real-time quantitative PCR (qPCR)
using a Stratagene Mx3005P system (Agilent Technologies, Santa
Clara, CA). Transcript levels of il33, cxcl10, and tslp were normalized
against transcript levels for hprt. Primer sequences are given in the
Supplementary Materials and Methods online..
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